Stockscreener 앱 받기
1.26
0.00%
0.00
시간 외 거래:
1.29
0.03
+2.38%
전일 마감가:
$1.26
열려 있는:
$1.22
하루 거래량:
231.34K
Relative Volume:
0.29
시가총액:
$10.65M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-42.73%
1개월 성능:
-58.14%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.13
$1.3378
1주일 범위
$1.13
$3.61
52주 변동 폭
$1.13
$9.55
Scienture Holdings Inc Stock (SCNX) Company Profile
명칭
Scienture Holdings Inc
전화
(800) 261 0281
주소
2420 BRUNELLO TRACE, LUTZ
SCNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
1.26 | 10.65M | 0 | 0 | 0 | 0.00 |
|
WBA
Walgreens Boots Alliance Inc
|
11.20 | 9.70B | 147.66B | -8.64B | -363.00M | -10.01 |
|
HITI
High Tide Inc
|
2.29 | 189.30M | 376.07M | -22.41M | 18.73M | -0.298 |
|
WGRX
Wellgistics Health Inc
|
2.89 | 135.06M | 0 | 0 | 0 | 0.00 |
|
PETS
Petmed Express Inc
|
4.11 | 85.93M | 270.52M | -6.08M | 17.42M | -0.2944 |
Scienture Holdings Inc 주식(SCNX)의 최신 뉴스
Scienture Holdings Secures Exclusive Naloxone Agreement - TipRanks
United States shares higher at close of trade; Dow Jones Industrial Average up 0.52% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.52% - Investing.com
Best Stocks Under $5 Right Now - Benzinga
Nasdaq Down Over 400 Points; Kroger Posts Upbeat Earnings - Benzinga
What's Going On With Scienture Stock Thursday? - Benzinga India
Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US - Marketscreener.com
Dow Tumbles 1%; US Initial Jobless Claims Decline - Benzinga
Scienture (SCNX) Soars In Pre-Hour Trading After Strategic Business Development - Stocks Telegraph
SCNX Stock Price and Chart — NASDAQ:SCNX - TradingView
Scienture To Commercially Launch Rezenopy -March 06, 2025 at 08:03 am EST - Marketscreener.com
Scienture Holdings rises on launch of opioid overdose antidote Rezenopy - TradingView
SCIENTURE to commercially launch REZENOPY®, a life-saving - GlobeNewswire
Can This New High-Strength Naloxone Treatment Transform the $189M Opioid Crisis Market? - StockTitan
Scienture Holdings (FRA:4E4) Preferred Stock : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
Biotech Stocks Facing FDA Decision In March 2025 - RTTNews
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga India
Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s - GlobeNewswire
Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics - The Manila Times
Scienture President to Keynote at Major SSX Pharma Conference, Spotlight Innovation Strategy - StockTitan
Scienture Holdings Board Restructures After Director Resignations - TipRanks
Scienture Holdings, Inc. Announces Director Resignations -January 17, 2025 at 04:05 pm EST - Marketscreener.com
Scienture Holdings Faces Nasdaq Compliance Challenge - TipRanks
Scienture Holdings, Inc. to Participate in The Microcap Conference 2025 - Nasdaq
Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025 - GlobeNewswire
Scienture Holdings to Present at Microcap Conference 2025: Strategic Growth Plans in Focus - StockTitan
Walgreens Boots Alliance (WBA) Stock Dips Amid Financial Challen - GuruFocus.com
Trxade Group, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019 - Marketscreener.com
Trxade Group, Inc. acquired Community Specialty Pharmacy, LLC from Nikul Panchal for $0.6 million. - Marketscreener.com
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041 - GlobeNewswire
Scienture Secures Crucial Patent Protection for Novel Losartan Oral Suspension Through 2041 - StockTitan
Scienture Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Scienture announces private placement of $3M of 10% secured convertible debentures - MSN
Scienture Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering and Entry into $50 Million Equity Line of Credit Agreement - The Manila Times
Scienture Holdings Secures Funding for Strategic Growth - TipRanks
Scienture Holdings Secures $62M in Strategic Financing, Including $12.2M Debenture Deal | SCNX Stock News - StockTitan
Walgreens Boots Alliance (WBA) Stock Surges Amid Market Activity - GuruFocus.com
Scienture Holdings: Q3 Earnings Snapshot - CTPost
White Mountains: Q3 Earnings Snapshot - AOL
TRxADE HEALTH, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 - Marketscreener.com
Scienture completes preferred stock conversion By Investing.com - Investing.com Australia
Scienture completes preferred stock conversion - Investing.com India
Scienture : Material Event Form 8 K - Marketscreener.com
Scienture Holdings Shares Insight with Investor Presentation - TipRanks
Gajan A. Mahendiran and Amudha Mahendiran acquired Westminster Pharmaceutical LLC from Trxade Group, Inc. for $1.6 million. - Marketscreener.com
Top Premarket Gainers - Marketscreener.com
Scienture Holdings Unveils New Identity Post-Merger - TipRanks
TRxADE Health changes its name to Scienture Holdings - AlphaStreet
Bats Reveal Superior Adaptation to Endure Heart Stress: National Heart Centre Singapore Partners Paratus Sciences Singapore to Accelerate Heart Failure Care - ForexTV.com
Nectero Medical Recognized as a 2024 AZBio Fast Lane Award Winner - ForexTV.com
Scienture Holdings Inc (SCNX) 재무 분석
Scienture Holdings Inc (SCNX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
5.31%
1.05%
자본화:
|
볼륨(24시간):